GLP1R and plasma cell myeloma: Our findings show that GLP-1 receptor agonist use is only robustly associated with a reduced risk for multiple myeloma, in agreement with a previous study of US veterans showing that GLP-1 receptor agonist use was associated with a decreased risk of progression from MGUS to multiple myeloma.11